Contraceptive efficacy and global licensing of 52 mg levonorgestrel intrauterine devices: does a Mirena last longer in New York than York?

IF 3.4 3区医学 Q1 FAMILY STUDIES

BMJ Sexual & Reproductive Health Pub Date : 2024-01-09 DOI:10.1136/bmjsrh-2023-201937

Zachary Nash, Annette Thwaites

引用次数: 0

查看原文本刊更多论文

52 毫克左炔诺孕酮宫内节育器的避孕效果和全球许可：Mirena 在纽约的使用时间比约克长吗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Sexual & Reproductive Health Medicine-Reproductive Medicine

CiteScore

5.10

自引率

6.10%

发文量

期刊介绍： BMJ Sexual & Reproductive Health is a multiprofessional journal that promotes sexual and reproductive health and wellbeing, and best contraceptive practice, worldwide. It publishes research, debate and comment to inform policy and practice, and recognises the importance of professional-patient partnership.